Patients with alectinib‐refractory ALK‐positive NSCLC who received brigatinib also showed relatively short PFS, even though the cases had an SM to brigatinib.12 Using better and new‐generation ALK‐TKIs on a priority basis might improve the prognosis of patients with ALK‐positive NSCLC. Here, ALK is linked to non-small cell lung carcinoma.